Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00669578 · ClinicalTrials.gov registry record · Phase 1
CC-4047 in Treating Patients With Myelofibrosis
A Phase 1 study, sponsored by Mayo Clinic.
- Completed
- Registry status
- Phase 1
- Development phase
- 77
- Enrollment target
NCT00669578: Completed Phase 1 study, sponsored by Mayo Clinic.
NCT00669578 is a Phase 1 study that has completed, run by Mayo Clinic. The registered enrollment target is 77 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00669578, a Phase 1 study, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 77 participants
- Enrollment target
Study Summary
RATIONALE: Biological therapies, such as CC-4047, may stimulate the immune system in different ways and stop cancer cells from growing. CC-4047 may also stop the growth of cancer cells by blocking blood flow to the cancer. PURPOSE: This trial is studying the side effects and best dose of CC-4047 and to see how well it works in treating patients with myelofibrosis.
Interventions
- DRUG CC-4047
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 77 participants |
| Start Date | 2008-05 |
| Est. Completion | 2019-12-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00669578
The ClinicalTrials.gov registry entry for NCT00669578 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 77 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which CC-4047 is the first listed.
NCT00669578 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00669578 about?
NCT00669578 is a clinical study titled "CC-4047 in Treating Patients With Myelofibrosis". RATIONALE: Biological therapies, such as CC-4047, may stimulate the immune system in different ways and stop cancer cells from growing. CC-4047 may also stop the growth of cancer cells by blocking blood flow to the cancer. PURPOSE: This trial is studying the side effects and best dose of CC-4047 an...
What is the current status of trial NCT00669578?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 77 participants. The study started on 2008-05. Estimated completion is 2019-12-12.
What interventions are being tested in trial NCT00669578?
The interventions under investigation include: CC-4047 (DRUG).
Who is sponsoring clinical trial NCT00669578?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.